A: Clinical trials show average weight loss of 2329% over 68 weeks
We support international shipping planning with document alignment, route selection, and timelines to help reduce clearance issues.
That clinical evidence doesn't automatically transfer to compounded preparations, which haven't been separately studied as finished products
At Cape Fear Physical Medicine and Rehab, we are committed to providing comprehensive care for patients facing challenges related to weight management and associated health conditions

These drug supply issues are a great opportunity to have patient management reviews, emphasise principles around healthy lifestyle, and review therapies including prescribing options or even de-prescribing if possible. Alternative treatment options suggested by the RACGP include: Liraglutide, which is administered once daily and has evidence of cardiovascular benefit, but is not subsidised by PBS SGLT-2 inhibitors, especially in those who also have cardiovascular disease, multiple cardiovascular risk factors and/or kidney disease DPP-4 inhibitors, which may be useful in those who do not have cardiovascular disease, multiple cardiovascular risk factors or kidney disease, and are unable to achieve optimal blood glucose levels Sulphonylureas or insulin (initiation or titrated doses), but these may lead to risks for hypoglycaemia and weight gain The twice daily exenatide (Byetta) is not recommended as a potential substitute, as it has been discontinued and is also no longer available

Melatonin induced suppression of ER stress and mitochondrial dysfunction inhibited NLRP3 inflammasome activation in COPD mice